Yunovia revealed on the 26th that the Korean MFDS has approved the IND application for a Phase 1 MAD study of ID110521156.

Axalbion Therapeutics Begins Phase 2 Trial for Chronic Cough by Administering AX-8, a New TRPM8 Agonist, to the First Patient.

Zai Lab to Share Early Findings from Phase 1 Study of ZL-1218, a Potential Anti-CCR8 Antibody for Advanced Tumor Therapy, at ESMO Congress 2024.

The European Commission greenlights RYBREVANT®▼ (amivantamab) alongside chemotherapy for adults with advanced EGFR-mutated NSCLC after previous treatments haven't worked.

Tonix Pharmaceuticals partners with Bilthoven Biologicals to advance TNX-801 Mpox vaccine development.

Ordspono™ (odronextamab) has received approval in the EU for treating relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma.

This approval broadens the scope of the MACI® (autologous cultured chondrocytes on porcine collagen membrane) label.

Roche has announced that the European Commission has granted approval for PiaSky® (crovalimab), an innovative recycling monoclonal antibody that targets the complement protein C5.

BioArctic AB revealed the publication of the findings from two phase-1 trials involving exidavnemab(ABBV-0805) in The Journal of Clinical Pharmacology.

SIFI revealed that the European Commission has granted approval for AKANTIOR® (polihexanide) for managing acanthamoeba keratitis (AK) in both adults and children aged 12 and over.

The European Commission grants approval to Celltrion’s SteQeyma® (CT-P43), a biosimilar version of Stelara® (ustekinumab), for treating several chronic inflammatory disorders.

Galapagos reveals FDA approval of its IND application for the Phase 1/2 ATALANTA-1 trial of CD19 CAR-T therapy, GLPG5101, in non-Hodgkin lymphoma that has relapsed or is refractory.